Preparation, in vitro characterization, pharmacokinetic, and pharmacodynamic evaluation of chitosan-based plumbagin microspheres in mice bearing B16F1 melanoma
- PMID: 20100068
- DOI: 10.3109/10717540903548447
Preparation, in vitro characterization, pharmacokinetic, and pharmacodynamic evaluation of chitosan-based plumbagin microspheres in mice bearing B16F1 melanoma
Abstract
The present study was aimed to evaluate the anti-tumor efficacy and systemic toxicity of chitosan-based plumbagin microspheres in comparison to free plumbagin. The optimized formulation had a mean particle size of 106.35 mum with an encapsulation efficiency of 80.12%. Pharmacokinetic studies showed a 22.2-fold increase in elimination half-life (t(1/2)) of plumbagin from chitosan microspheres as compared to free plumbagin. Administration of plumbagin microspheres resulted in a significant tumor growth inhibition and reduced systemic toxicity. These results suggest that chitosan-based microspheres could be a promising strategy for the systemic delivery of anti-cancer agents like plumbagin.
Similar articles
-
Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL/6J mice bearing B16F1 melanoma.Drug Deliv. 2011 Sep-Oct;18(7):511-22. doi: 10.3109/10717544.2011.595840. Epub 2011 Jul 28. Drug Deliv. 2011. PMID: 21793763
-
Antitumor and antifertility activities of plumbagin controlled release formulations.Indian J Exp Biol. 1997 Apr;35(4):374-9. Indian J Exp Biol. 1997. PMID: 9315238
-
Preparation and in vitro release of spray-dried chitosan microspheres for levofloxacin delivery.J Control Release. 2011 Nov 30;152 Suppl 1:e70-1. doi: 10.1016/j.jconrel.2011.08.129. J Control Release. 2011. PMID: 22195935 No abstract available.
-
Plumbagin and Its Role in Chronic Diseases.Adv Exp Med Biol. 2016;929:229-246. doi: 10.1007/978-3-319-41342-6_10. Adv Exp Med Biol. 2016. PMID: 27771927 Review.
-
Perspectives on medicinal properties of plumbagin and its analogs.Med Res Rev. 2012 Nov;32(6):1131-58. doi: 10.1002/med.20235. Epub 2010 Nov 9. Med Res Rev. 2012. PMID: 23059762 Review.
Cited by
-
Pharmacological Features and Therapeutic Implications of Plumbagin in Cancer and Metabolic Disorders: A Narrative Review.Nutrients. 2024 Sep 8;16(17):3033. doi: 10.3390/nu16173033. Nutrients. 2024. PMID: 39275349 Free PMC article. Review.
-
Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid-Polymer Hybrid Nanoparticles.Int J Nanomedicine. 2021 Apr 6;16:2615-2631. doi: 10.2147/IJN.S293480. eCollection 2021. Int J Nanomedicine. 2021. PMID: 33854311 Free PMC article.
-
Transferrin-bearing liposomes entrapping plumbagin for targeted cancer therapy.J Interdiscip Nanomed. 2019 Jun 26;4(2):54-71. doi: 10.1002/jin2.56. eCollection 2019 Jun. J Interdiscip Nanomed. 2019. PMID: 31341642 Free PMC article.
-
Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation.J Mater Sci Mater Med. 2011 Apr;22(4):865-78. doi: 10.1007/s10856-011-4274-y. Epub 2011 Mar 23. J Mater Sci Mater Med. 2011. PMID: 21431353
-
Advances in Chitosan-based Drug Delivery Systems in Melanoma: A Narrative Review.Curr Med Chem. 2024;31(23):3488-3501. doi: 10.2174/0929867330666230518143654. Curr Med Chem. 2024. PMID: 37202890 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources